Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole dose comparison for prevention of risperidone-induced hyperprolactinemia in schizophrenia
ChiCTR1900027504Phase 4Completed
- Sponsor
- Shandong Mental Health Center
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole and risperidone in schizophrenia (3 arms), sponsored by Shandong Mental Health Center. Primary endpoint: Serum prolactin levels at week 8. Started Mar 2017; status: completed.
02
Drugs
aripiprazolerisperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR1900027504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027504.